$IMUX
Immunic Inc

2022 Q1 Form 10-Q Financial Statement

#000128077622000012 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.990M $20.87M
YoY Change -80.88% 708.91%
% of Gross Profit
Research & Development $17.45M $11.52M
YoY Change 51.45% 79.03%
% of Gross Profit
Depreciation & Amortization $21.00K $14.00K
YoY Change 50.0% 0.0%
% of Gross Profit
Operating Expenses $21.44M $32.39M
YoY Change -33.82% 259.3%
Operating Profit -$21.44M -$32.39M
YoY Change -33.82% 259.3%
Interest Expense $7.000K $30.00K
YoY Change -76.67% 50.0%
% of Operating Profit
Other Income/Expense, Net $627.0K -$2.147M
YoY Change -129.2% -507.4%
Pretax Income -$20.81M -$34.53M
YoY Change -39.74% 306.71%
Income Tax
% Of Pretax Income
Net Earnings -$20.81M -$34.53M
YoY Change -39.75% 306.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$1.63
Diluted Earnings Per Share -$0.74 -$1.63
COMMON SHARES
Basic Shares Outstanding 28.13M shares 21.17M shares
Diluted Shares Outstanding 28.13M shares 21.17M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $95.71M $114.8M
YoY Change -16.63% 517.2%
Cash & Equivalents $95.70M $114.8M
Short-Term Investments
Other Short-Term Assets $1.548M $886.0K
YoY Change 74.72% 32.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $115.9M $120.3M
YoY Change -3.66% 409.68%
LONG-TERM ASSETS
Property, Plant & Equipment $155.0K $190.0K
YoY Change -18.42% 146.75%
Goodwill $32.97M $32.97M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $42.00K $42.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $34.04M $34.44M
YoY Change -1.17% 2.23%
TOTAL ASSETS
Total Short-Term Assets $115.9M $120.3M
Total Long-Term Assets $34.04M $34.44M
Total Assets $149.9M $154.7M
YoY Change -3.1% 170.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.288M $10.05M
YoY Change -67.28% 601.68%
Accrued Expenses $7.520M $5.827M
YoY Change 29.05% 47.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.46M $16.36M
YoY Change -29.95% 158.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $502.0K $900.0K
YoY Change -44.22% 80.0%
Total Long-Term Liabilities $502.0K $922.0K
YoY Change -45.55% 95.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.46M $16.36M
Total Long-Term Liabilities $502.0K $922.0K
Total Liabilities $11.96M $17.28M
YoY Change -30.78% 153.94%
SHAREHOLDERS EQUITY
Retained Earnings -$217.7M -$138.5M
YoY Change 57.18% 102.49%
Common Stock $3.000K $2.000K
YoY Change 50.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $138.0M $137.4M
YoY Change
Total Liabilities & Shareholders Equity $149.9M $154.7M
YoY Change -3.1% 170.06%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$20.81M -$34.53M
YoY Change -39.75% 306.9%
Depreciation, Depletion And Amortization $21.00K $14.00K
YoY Change 50.0% 0.0%
Cash From Operating Activities -$20.68M -$12.95M
YoY Change 59.72% 17.4%
INVESTING ACTIVITIES
Capital Expenditures $12.00K $10.00K
YoY Change 20.0% 150.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$12.00K -$10.00K
YoY Change 20.0% 150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $29.64M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $29.64M $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$20.68M -$12.95M
Cash From Investing Activities -$12.00K -$10.00K
Cash From Financing Activities $29.64M $0.00
Net Change In Cash $8.847M -$12.61M
YoY Change -170.14% 16.88%
FREE CASH FLOW
Cash From Operating Activities -$20.68M -$12.95M
Capital Expenditures $12.00K $10.00K
Free Cash Flow -$20.69M -$12.96M
YoY Change 59.69% 17.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2022Q1 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#Liabilities
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36201
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Immunic, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2358443
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1200 Avenue of the Americas
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2022Q1 dei City Area Code
CityAreaCode
332
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
255-9818
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Trading Symbol
TradingSymbol
IMUX
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
152000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
32970000 USD
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30540383 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95710000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86863000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20169000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18125000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
115879000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
104988000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
584000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
948000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
32970000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
874000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 USD
CY2022Q1 us-gaap Assets
Assets
149920000 USD
CY2021Q4 us-gaap Assets
Assets
139100000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3288000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3745000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7520000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7071000 USD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
649000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
585000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11457000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11401000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
502000 USD
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
502000 USD
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
584000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
11959000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
11985000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29240383 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29240383 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26335418 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26335418 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
355949000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
324237000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-310000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-252000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217681000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196873000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
137961000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
127115000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149920000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139100000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17445000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11519000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3990000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3618000 USD
CY2022Q1 vtl Royalty Settlement Agreement Sales Net
RoyaltySettlementAgreementSalesNet
0 USD
CY2021Q1 vtl Royalty Settlement Agreement Sales Net
RoyaltySettlementAgreementSalesNet
17250000 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
21435000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
32387000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21435000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32387000 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
620000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2175000 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
627000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2147000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20808000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34534000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28127288 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28127288 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21174698 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21174698 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20808000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34534000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-58000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2991000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20866000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31543000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
127115000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20808000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2069000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-58000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
918000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
137961000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
158785000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34534000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1579000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2991000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
137446000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20808000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34534000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-149000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2505000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2069000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1579000 USD
CY2022Q1 us-gaap Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable
AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
0 USD
CY2021Q1 us-gaap Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable
AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
-8625000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2267000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-410000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-350000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6773000 USD
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
558000 USD
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1714000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-53000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-34000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20681000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12948000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29638000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29643000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-103000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8847000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12613000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86863000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127452000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95710000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114839000 USD
CY2022Q1 us-gaap Stock Issued1
StockIssued1
0 USD
CY2021Q1 us-gaap Stock Issued1
StockIssued1
8625000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
435000 USD
CY2022Q1 dei Entity Number Of Employees
EntityNumberOfEmployees
55 employee
CY2022Q1 vtl Number Of Development Programs Pursued
NumberOfDevelopmentProgramsPursued
3 program
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217700000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196900000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
289200000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95700000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div>
CY2022Q1 vtl Number Of Financial Institutions Used For Cash Deposits
NumberOfFinancialInstitutionsUsedForCashDeposits
2 financialInstitution
CY2022Q1 us-gaap Depreciation
Depreciation
21000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
14000 USD
CY2021Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2022Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2022Q1 vtl Lessee Operating Leases Number Of Existing Leases
LesseeOperatingLeasesNumberOfExistingLeases
2 lease
CY2022Q1 vtl Lessee Operating Leases Number Of Existing Leases
LesseeOperatingLeasesNumberOfExistingLeases
2 lease
CY2022Q1 vtl Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
15406000 USD
CY2021Q4 vtl Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
14853000 USD
CY2022Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
585000 USD
CY2021Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
279000 USD
CY2022Q1 vtl Research And Development Tax Incentive Current
ResearchAndDevelopmentTaxIncentiveCurrent
2630000 USD
CY2021Q4 vtl Research And Development Tax Incentive Current
ResearchAndDevelopmentTaxIncentiveCurrent
1871000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1548000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1122000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20169000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18125000 USD
CY2022Q1 vtl Clinical Costs Payable Current
ClinicalCostsPayableCurrent
2885000 USD
CY2021Q4 vtl Clinical Costs Payable Current
ClinicalCostsPayableCurrent
3427000 USD
CY2022Q1 vtl Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
182000 USD
CY2021Q4 vtl Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
72000 USD
CY2022Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
221000 USD
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
246000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3288000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3745000 USD
CY2022Q1 vtl Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
6970000 USD
CY2021Q4 vtl Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
6214000 USD
CY2022Q1 vtl Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
85000 USD
CY2021Q4 vtl Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
96000 USD
CY2022Q1 vtl Accrued Compensation Current
AccruedCompensationCurrent
314000 USD
CY2021Q4 vtl Accrued Compensation Current
AccruedCompensationCurrent
674000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
151000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
87000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7071000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7520000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404000 USD
CY2022Q1 vtl Shelf Registration Agreement Commission Percent Of Gross Proceeds On Sale Of Common Stock
ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
0.030
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
408000 USD
CY2022Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
245000 USD
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
177000 USD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
649000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
585000 USD
CY2022Q1 vtl Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.06
CY2022Q1 vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
130000 USD
CY2021Q1 vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
94000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
339000 USD
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
303000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
228000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
114000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2022Q1 vtl Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
984000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
78000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
906000 USD
CY2022Q1 us-gaap Contractual Obligation
ContractualObligation
3000000 USD
CY2016Q2 vtl Asset Purchase Agreement Royalties As Percent Of Aggregated Net Sales
AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
0.044
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120070 shares
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1500000 USD
CY2020Q4 vtl Maximum Aggregate Offering Price Of Securities Under Shelf Registration
MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
250000000 USD
CY2022Q1 vtl Number Of Votes Per Each Share Of Common Stock
NumberOfVotesPerEachShareOfCommonStock
1 vote
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4257146 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
21100000 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M8D

Files In Submission

Name View Source Status
0001280776-22-000012-index-headers.html Edgar Link pending
0001280776-22-000012-index.html Edgar Link pending
0001280776-22-000012.txt Edgar Link pending
0001280776-22-000012-xbrl.zip Edgar Link pending
exhibit421111.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imux-033120xexhibit31111.htm Edgar Link pending
imux-033120xexhibit31211.htm Edgar Link pending
imux-033120xexhibit32111.htm Edgar Link pending
imux-033120xexhibit32211.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20220331.htm Edgar Link pending
vtl-20220331.xsd Edgar Link pending
vtl-20220331_cal.xml Edgar Link unprocessable
vtl-20220331_def.xml Edgar Link unprocessable
vtl-20220331_g1.jpg Edgar Link pending
vtl-20220331_htm.xml Edgar Link completed
vtl-20220331_lab.xml Edgar Link unprocessable
vtl-20220331_pre.xml Edgar Link unprocessable